FRA:IX1 • US45168D1046
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IDEXX LABORATORIES INC (IX1.DE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-08-13 | Credit Suisse | Maintains | Outperform |
| 2021-08-03 | Goldman Sachs | Maintains | Neutral |
| 2021-08-02 | Barclays | Maintains | Overweight |
| 2021-07-12 | Guggenheim | Downgrade | Buy -> Neutral |
| 2021-02-17 | Barclays | Initiate | Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.661B 8.72% | 3.898B 6.46% | 4.304B 10.42% | 4.77B 10.83% | 5.18B 8.60% | 5.658B 9.23% | 6.161B 8.89% | 6.87B 11.51% | 7.77B 13.10% | 8.424B 8.42% | 9.096B 7.98% | |
| EBITDA YoY % growth | 1.213B 19.63% | 1.263B 4.09% | 1.509B 19.53% | 1.691B 12.03% | 1.871B 10.64% | 2.086B 11.49% | 2.302B 10.35% | 2.793B 21.33% | 3.102B 11.06% | 3.426B 10.44% | 3.761B 9.78% | |
| EBIT YoY % growth | 1.098B 21.73% | 1.133B 3.15% | 1.364B 20.43% | 1.531B 12.22% | 1.705B 11.37% | 1.905B 11.73% | 2.114B 10.97% | 2.619B 23.89% | 2.917B 11.38% | 3.23B 10.73% | 3.552B 9.97% | |
| Operating Margin | 30.00% | 29.07% | 31.70% | 32.10% | 32.92% | 33.67% | 34.31% | 38.12% | 37.54% | 38.34% | 39.05% | |
| EPS YoY % growth | 10.07 25.40% | 11.25 11.72% | 13.07 16.18% | 14.82 13.42% | 16.71 12.69% | 18.95 13.43% | 20.96 10.62% | 24.89 18.73% | 30.15 21.15% | 33.78 12.04% | 37.57 11.20% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 3.48 17.56% | 4.02 10.78% | 3.81 12.05% | 3.51 13.96% | 3.80 9.24% | 4.43 10.25% | 4.18 9.69% | 3.88 10.53% | 4.41 15.92% | 5.16 16.41% | 4.88 16.68% |
| Revenue Q2Q % growth | 1.142B 14.38% | 1.224B 10.32% | 1.212B 9.66% | 1.178B 8.02% | 1.21B 5.95% | 1.313B 7.27% | 1.316B 8.58% | 1.28B 8.66% | 1.337B 10.50% | 1.444B 9.98% | 1.445B 9.80% |
| EBITDA Q2Q % growth | 403.23M 15.01% | 455.23M 2.79% | 436.34M -5.41% | 405.34M -12.03% | 441.84M 9.58% | 489.63M 7.56% | 470.75M 7.89% | 428.6M 5.74% | N/A | N/A | N/A |
| EBIT Q2Q % growth | 365.11M 15.35% | 415.51M 11.38% | 393.45M 10.88% | 354.2M 12.23% | 403.55M 10.53% | 454.95M 9.49% | 435.77M 10.76% | 384.24M 8.48% | N/A | N/A | N/A |
All data in USD
22 analysts have analysed IX1.DE and the average price target is 692.16 EUR. This implies a price increase of 34.5% is expected in the next year compared to the current price of 514.6.
IDEXX LABORATORIES INC (IX1.DE) will report earnings on 2026-04-29, before the market open.
The consensus EPS estimate for the next earnings of IDEXX LABORATORIES INC (IX1.DE) is 3.48 EUR and the consensus revenue estimate is 1.14B EUR.
The expected long term growth rate for IDEXX LABORATORIES INC (IX1.DE) is 8.98%.